Tag Archives: patients

Pinellas vaccine vendor to contact patients registered for vaccine

There will be no more mad dashes to score an appointment for a coronavirus vaccine through Pinellas County’s online portal.

Beginning with the next shipment of vaccine from the state of first doses for residents 65 and older, Pinellas County’s contracted vendor, CDR Maguire, will contact pre-registered patients to schedule an appointment.

The new arrangement will replace the first-come first-served protocol that’s been in place since the county launched the CDR online portal and call center last month. In that system, users had to log on the website or call on a specific date and time in order to book an appointment for a limited number of doses received that week.

Patients who did not receive appointments were met with a frozen website, error messages and wasted hours trying to get through.

“We understand people’s frustration on that,” county administrator Barry Burton said at a virtual press conference on Friday. “We’ve been working tirelessly with the vendor to fix it. A lot of people said ‘fire them.’ But where do I go and how long would it take to stand up a new system versus fix this?”

Pinellas County signed a $3 million contract on Jan. 10 with CDR Maguire, a Miami-based emergency management firm that set up an online portal and phone bank to make appointments and track doses the county is administering in partnership with the Florida Department of Health.

Burton did not provide a date of when the county expects to get another batch of vaccine for residents to receive first doses. He said next week’s shipment will go towards those patients in need of a second dose.

Officials urged residents to also seek the vaccine through other distributors, including pharmacies, community health centers and hospitals – noting all of those outlets have their own registration and protocols.

County Commission Chair Dave Eggers acknowledged the dysfunction but noted that all 28,000 doses the county has received in conjunction with the Department of Health in Pinellas to date have been successfully administered “in arms.”

“We have made some mistakes as far as rolling out the vaccine and actually having the signing up, the registration process and actually getting appointments,” county commission chair Dave Eggers said in the conference Friday. “Many of you have experienced anxiety because of that, frustration, anger, fear and for that I’m really sorry. We need to do better.”

Following more than a month of confusion over how to score an appointment for a vaccine, Florida last week unveiled a new statewide pre-registration system. But not all counties are participating in the system. Burton said he did not even know about the state’s new system until Friday.

Pinellas is operating its own sites to administer the vaccine that are run by county paramedics. Dr. Ulyee Choe, Director of the Florida Department of Health in Pinellas said officials hope to be able to offer more access points so transportation and other burdens are not a factor for residents.

But a lack of supply remains an issue. The vaccine is still limited to people ages 65 and older, health care works and long-term care facility patients.

But with 250,000 seniors in Pinellas, Burton said the demand is overwhelming.

“The reality is 90 percent of the people coming into that are going to be unhappy because we don’t have the supply necessary,” Burton said. “But the people that are there should be able to see where their at, know whether they’re able to be able to get a vaccine or they have to come back at a later time.”

Patients can register for a vaccine through Pinellas County by going to www.patientportalfl.com or calling 844-770-8548. The vendor will call pre-registered patients when appointments are available.

• • •

HOW CORONAVIRUS IS SPREADING IN FLORIDA: Find the latest numbers for your county, city or zip code.

VACCINES Q & A: Have coronavirus vaccine questions? We have answers, Florida.

FACE MASKS: Read the latest on guidelines, tips for comfort and long-term wear

GET THE DAYSTARTER MORNING UPDATE: Sign up to receive the most up-to-date information.

THE CORONAVIRUS SCRAPBOOK: We collected your stories, pictures, songs, recipes, journals and more to show what life has been like during the pandemic.

A TRIBUTE TO THE FLORIDIANS TAKEN BY THE CORONAVIRUS: They were parents and retirees, police officer and doctors, imperfect but loved deeply.

HAVE A TIP?: Send us confidential news tips

We’re working hard to bring you the latest news on the coronavirus in Florida. This effort takes a lot of resources to gather and update. If you haven’t already subscribed, please consider buying a print or digital subscription.

Read original article here

Tel Aviv hospital cures 29 of 30 COVID-19 patients in days, it says

Twenty-nine out of 30 moderate-to-severe COVID-19 patients who were administered a treatment developed by Tel Aviv Sourasky Medical Center (Ichilov Hospital) as part of a Phase I trial recovered from the disease and were released from the hospital within three to five days, the hospital said Friday.

The 30th patient also recovered but it took longer.

The patients were given Prof. Nadir Arber’s EXO-CD24 COVID-19 treatment, which is based on CD24-enriched exosomes and is meant to fight the cytokine storm that is associated with many of the world’s COVID-19 deaths.

A cytokine storm is when the immune system essentially goes into overdrive and begins attacking healthy cells. Exosomes are responsible for cell-to-cell communication. In this case, the exosomes deliver the CD24 protein to the lungs, which helps calm down the immune system.

“This protein is located on the surface of cells and has a well-known and important role in regulating the immune system,” explained Dr. Shiran Shapira, who works in Arber’s lab.

Arber has been researching exosomes for the better part of two decades. He said it took about six months from the time the idea of using this treatment in the battle against COVID-19 was raised until it was first tested in humans. 

The treatment is inhaled once a day for a few minutes at a time for five days. It directly targets the lungs, the site of the storm, as opposed to other treatments that could be given systemically and hence cause severe side effects, Arber explained.

The majority of the patients who received EXO-CD24 showed significant improvement within two days.

The hospital has appealed to the Health Ministry to move forward with further clinical trials. Once approved, the treatment can be tried on additional patients.Prof. Nadir Arber (Credit: Ichilov Hospital)

“This is an innovative treatment that can be produced quickly and efficiently at a low cost,” Arber explained. “Even if the vaccines do what they are supposed to, and even if no new mutations are produced, then still, in one way or another, coronavirus will remain with us.”

The head of Suourasky, Prof. Ronni Gamzu hailed the treatment as “innovative and sophisticated” and said that the results of the Phase I trial “give us all an expression of confidence in the method.” He added that he would personally assist Arber in obtaining the approvals needed from the Health Ministry to further his research.
Gazmu served as Israel’s coronavirus commissioner from August to November 2020. He said that the international understanding is that alongside vaccines “it is especially important to develop drugs to treat the disease..”I am proud that Ichilov … is perhaps bringing a blue-and-white solution to a terrible global pandemic,” he concluded. 

This is not the first Israeli drug to show promise in the treatment of COVID-19. 

Last year, Hadassah-University Medical Center reported similar results from the use of the drug Allocetra, which was developed by the Enlivex Company based on research by a Hadassah doctor, Prof. Dror Mevorach. Similar to EXO-CD24, Allocetra is meant to treat the overreaction of the immune system.Also, Israel’s Pluristem Therapeutics has been investigating the use of its PLX-PAD placenta-derived cellular therapy, which the company has said it hopes will play a meaningful role in mitigating the tissue-damaging effects of COVID-19 on the lungs. The company is now engaged in clinical trials, as well.



Read original article here

Cancer doctors consider Covid-19 vaccines for patients

It’s a question that has been on the minds of researchers and oncologists long before the Pfizer and Moderna vaccine rollouts began. Although there is a consensus that the vaccines are safe for most cancer patients, according to the American Cancer Society and others in the medical community, research into whether they will be effective for cancer patients is still a data-free zone.
The American Cancer Society recommends that cancer patients talk to their doctors before getting any type of vaccine because all patients and their courses of treatment are different.

There are several factors that may require a cancer patient to delay vaccination, including recent stem cell transplants or other recent use of therapy agents known to reduce vaccine efficacy, according to Dr. Laura Makaroff, the American Cancer Society’s Senior Vice President for Prevention and Early Detection.

“As far as safety of the vaccine, every situation for every patient with cancer is a little different. And there’s a spectrum of where any one patient might be in their cancer journey,” Makaroff told CNN. “The Covid-19 vaccine is definitely safe for people with cancer but it’s important that patients have a conversation with their healthcare provider and their cancer care team to determine when is the right time to have the vaccine.”

“All the guidance that we’re seeing — the American Cancer society and other leading oncology groups — is that Covid-19 immunization is recommended for patients in active therapy, but we really understand that there are limited safety and efficacy data on these patients,” Makaroff said.

Even with limited data, many cancer experts, medical groups, and doctors are making a big push for vaccinating most cancer patients — especially those cancer patients most at risk during the pandemic.
“The potential benefits far outweigh the risks,” said Dr. Brian Koffman, chief medical officer for CLL Society, a group that represents patients with chronic lymphocytic leukemia, the most common adult form of leukemia in the western world.

“Despite the lack of safety data specifically in patients with CLL (chronic lymphocytic leukemia), SARS-Cov-2 vaccination is anticipated to be safe.”

Patients with chronic lymphocytic leukemia who develop symptomatic Covid-19 have an 89% risk of hospitalization, Koffman told CNN, based on a study published in the journal Nature.

CLL is characterized by a weakened immune system. The immunocompromization is so severe that CLL patients are advised to avoid live vaccines such as the ones for measles or yellow fever.

And a weakened immune system also means these cancer patients have an increased risk of death due to Covid-19, according to Dr. Chaitra Ujjani, a physician at Seattle Cancer Care Alliance and oncology professor at the University of Washington School of Medicine. The Nature study, conducted the by European Research Initiative on CLL, found that the mortality rate for CLL patients with symptomatic coronavirus was 31%.

“The thing that people don’t quite realize is that the impaired immune system in CLL patients — due to the disease or some of the treatments for the disease — can actually impact your response to vaccination,” Ujjani told CNN.

“We recommend the Covid-19 vaccines for our patients … but we’re not really sure how effective it’s going to be,” she added. “Patients with blood cancers are typically excluded from the clinical trials evaluating the efficacy of the vaccine.”

Cancer-specific vaccine trials underway

To remedy the lack of data, Ujjani is launching a research study involving 500 CLL patients across the country — all of whom are already slated to receive the vaccine from their doctor or pharmacist — to determine what kind of immune response they will have to the commercially available vaccines.

The study, which is a collaboration between more than 10 medical institutions, will be the first of its kind and may bring more clarity for cancer patients.
The Seattle Cancer Care Alliance is conducting similar trials for other cancer types, including certain immune system and blood cancers, Ujjani said.

Advocacy groups for other more prevalent types of cancer are also encouraging cancer patients to get vaccinated as soon as possible. The Lung Cancer Action Network recently asked the US Advisory Committee on Immunization Practices to give lung cancer patients expedited access to the vaccines.

“Because COVID-19 is primarily a respiratory condition, this disease presents a unique challenge to lung cancer patients, who are at extremely high risk of hospitalization and death from COVID-19,” said the group in a letter.

More research urgently needed

The scientific community agrees that more research is needed to determine the effectiveness of Covid-19 vaccines in cancer patients — and many doctors are working around the clock to get more trials off the ground.

“We need these data so that we can better inform patients and better prioritize the allocation of the vaccines. If these vulnerable patients form an adequate immune response, we should certainly vaccinate them as early as possible,” Dr. Elad Sharon, senior investigator at the National Cancer Institute, told CNN via email.

“But, if research efforts show that these patients fail to form a protective response to these vaccines, then what we will need to do will be to vaccinate everyone around these patients first, so that our medically vulnerable patients are most protected by the people living with them and caring for them.”

Ujjani added, “We’re all working really hard to answer this question, but it’s hard because we’ve been working kind of against the clock as the vaccines just became available.”

“A lot of our patients have suffered in isolation and fear, and they’re not sure they’re going to get back to a normal life,” Ujjani told CNN. “So every oncologist is interested to see how their patients will respond to the vaccine.”

Correction: An earlier version of this story misnamed the CLL Society by including the words of the acronym.

Read original article here

Pakistan battles ‘tsunami’ of Covid-19 patients with few vaccines in sight

The video link was set up at the private South City Hospital in Karachi to enable relatives to feel closer to their loved ones in the ICU, as visits inside that facility are prohibited.

The screen is the closest Ameen has come to seeing his father for about 18 months. The 33-year-old flew back to Pakistan from his home in Melbourne, Australia, when his dad was hospitalized.

“Seeing him on a screen like that was pretty traumatizing for me,” said Ameen. “We told him that yes, I am here, and I want to see him healthy and smiling back again.”

But Ameen’s father didn’t survive. Instead, he became one of thousands of Pakistanis to die from the virus.

For many countries struggling in the Western world as winter cases surge, the arrival of vaccines has provided a light at the end of the tunnel. But in places like Pakistan, that tunnel remains in near darkness.

“The vaccine is not here in this country for the foreseeable future,” says Dr. Nashwa Ahmad, Coordinator of Covid Services and Research and Development at South City Hospital.

“That means our health care workers still have to continue to do their jobs, (and) endless hours, without the protection of the vaccine.

“A vaccine would definitely have given us the additional boost we needed to continue on with fighting the disease.”

The hospital has been overwhelmed with “a tsunami of patients,” Ahmad says. The three Covid-19 ICU wards are full, and more patients are waiting in ambulances outside.

“We are full, we have patients waiting, we have families who are suffering, we have patients at home, sick patients at home, patients who are on oxygen, we just don’t have space in hospitals,” she says.

So far, Pakistan has officially recorded more than half a million cases of Covid-19, and more than 11,600 related deaths — although health officials tell CNN that testing is not sufficient to reflect the true picture.
Pakistan has secured 1.2 million doses from China’s Sinopharm, with 500,000 expected to arrive this weekend, but they will barely make a dent in vaccinating the country’s population of 216 million. Health workers in major cities are due to start receiving shots next week, and negotiations are underway for vaccines from other manufacturers, says Asad Umar, the chief of the National Command and Operations Centre.

Pakistan’s health minister confirmed announced this week that it will receive 17 million doses of AstraZeneca’s coronavirus vaccine in 2021.

About 6 million of those doses are expected in the country in March with the remaining batches following in the second quarter of the year.

A ‘humongous logistical challenge’

Pakistan is also pinning its hopes on COVAX, the global initiative to provide up to 2 billion vaccine doses to the most vulnerable 20% of the world’s poorest populations, formed by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations.

“This is an unprecedented effort,” said Aurélia Nguyen, managing director of COVAX. “We have never rolled out this number of vaccines in this short (a) time.”

The ambitious COVAX program is aimed at ensuring equitable vaccines for all, to end the “acute” phase of the pandemic. Rollouts are expected to start in February, although the exact timeline depends on regulatory approvals of vaccines in each country — as well as their readiness to administer them properly.

Such an approach presents a “humongous logistical challenge,” especially for vaccines such as Pfizer-BioNTech which require ultra-cold chain refrigeration, said Benjamin Schreiber, deputy chief of the global immunization program at the UN International Children’s Emergency Fund (UNICEF).

UNICEF will help deliver the vaccines on the ground in developing countries, where it already has a presence.

“We’ve never seen an introduction of a vaccine to so many countries in one go, that’s absolutely new, and really no vaccine has ever been deployed and introduced in so many countries so quickly,” Schreiber said.

This uncertainty is already creating anxiety in countries reliant on COVAX, he added. “Countries are looking at COVAX and don’t see yet vaccines arriving, while they see some countries are making bilateral deals, and that creates kind of a panic,” Schneider said.

Vaccine nationalism

Pakistan is one of 92 lower-income countries eligible for free vaccines from COVAX. Another 98 wealthier countries will also purchase doses through the organization, using it as a middle man to streamline negotiations with vaccine makers — and to prevent vaccine nationalism.
The concept of vaccine nationalism has become a significant global concern, highlighted by the ongoing public spat between the European Union and British-Swedish drug maker AstraZeneca, which recently informed the bloc it would not be able to supply the number of vaccines the EU had hoped for by the end of March. EU leaders are furious the company appears to be fulfilling its deliveries for the UK market and not theirs.

“I think we can expect that it’s not going to be all smooth sailing, as the vaccine manufacturing is scaled up and distribution happens,” Nguyen said. “I think it’s important for everyone to be able to be accountable to the commitments that they’ve made.”

Nguyen said it was inevitable that initial vaccine demand would outstrip supply. “This is exactly the reason why COVAX was created, to avoid a bidding war for vaccines,” she added.

“Without concerted effort, lower-income countries will be left behind because of the restrictions of their financial capabilities to be able to buy vaccines.”

COVAX has so far raised $6 billion from wealthier countries and other organizations, including a giant injection of $4 billion from the US, approved by Congress in December. The Biden administration also announced it would join the global initiative.

“That’s been a hugely welcome move on the part of the Biden-Harris administration,” Nguyen said. “I think it’s a very strong endorsement of the COVAX facility, of the aim to have a global and multilateral approach to fair and equitable access for Covid-19 vaccines.”

Vaccinating 20% of people in the world’s poorest countries, however, won’t be enough to help their populations reach herd immunity. Although COVAX plans to expand the program for as long as it is needed, analysis by the Economist Intelligence Unit suggests huge swathes of Asia and Africa will not see widespread availability of Covid-19 vaccines until 2022 or 2023.
Pakistan’s Prime Minister, Imran Khan, addressed this issue during the UN Conference on Trade and Development on January 25, calling for more to be done to help vaccinate the developing world.

“It will take much longer for the vaccine to fully cover the global south,” Khan said. “The coverage of the COVAX facility must be expanded. This will enable the developing countries to spend their precious resources on socioeconomic development needs.”

Many of the richer countries self-funding vaccines in COVAX do understand the importance of a united solution to the pandemic. Singapore, for example, has pledged $5 million to COVAX to fund vaccines for poorer countries.

“This is borderless, this is a problem without a passport, it doesn’t need a visa,” says Umej Bhatia, Singapore’s Permanent Representative to the United Nations Office and member of the “Friends of COVAX” group.

“If we don’t help solve this problem, we will have this problem for a longer time.”

But still, the global race to procure vaccines directly from manufacturers is gathering pace.

“Vaccine nationalism is the is the evil twin of COVAX,” says Jerome Kim, Director General of the International Vaccine Institute. “A lot of the countries that signed up for COVAX, the high-income countries in particular, hedge their bets by putting in pre-orders for Covid-19 vaccines.”

“(Now) COVAX is at the back of the line,” Kim said, although he added the situation could change with wealthier countries ultimately donating excess vaccines back to COVAX.

Alarm over the growing chasm has been raised by the WHO director-general, Tedros Adhanom Ghebreyesus.

“I need to be blunt,” he said. “The world is on the brink of a catastrophic moral failure. And the price of this failure will be paid with lives and livelihoods in the world’s poorest countries.”

Of 39 million vaccines administered globally by January 18, Ghebreyesus said, just 25 doses were given in a lower-income country.

“Not 25 million, not 25,000, just 25,” he said.

“I think the rich-poor divide is always going to be there,” said Dr. Naseem Salahuddin, Head of the Department of Infectious Diseases at the public Indus Hospital in Karachi. “We have learned to accept that the West is always privileged. Since they have invested all the money in developing the vaccines, they’re going to be in the front line anyway.”

Internal divisions

As the vaccine divide grows internationally, an internal divide between the rich and poor is also expected to emerge — and for many middle-class and wealthy Pakistanis, flying abroad might be the only option to receive a vaccine anytime soon.

The market for vaccine tourism is taking shape. An exclusive lifestyle club called Knightsbridge Circle, based in London, has started offering trips to Dubai to enable the ultra-rich to skip the vaccine queue. For its members, who pay 25,000 British pounds ($34,000) a year, the package includes flights, accommodation, and two doses of the vaccine three weeks apart.

From this week, the company is also offering a package for non-members, which starts at 10,000 British pounds ($13,685), including two doses of the vaccine plus transfers from the airport and the vaccine center. The scheme is only be available to the over-65s or those with pre-existing conditions. The founder, Stuart McNeill, said they decided to do this in the UAE because the population already has free access to the vaccine.

For Daniyal Ameen in Karachi, the option of paying for his family to receive vaccines abroad is an attractive prospect.

As well as losing his father to Covid-19, his mother was also hospitalised with the coronavirus, although she has since recovered.

“If there is an opportunity for me to get myself or my family vaccinated, of course I’m going to get that,” he says. “Whatever it takes to do that, because I have seen that very personally that all my family members were affected by Covid.”

As a middle-class family, they’re among the lucky ones who may have the financial means to make it happen.

Pakistan’s anti-vaxxers

Bigger problems may also face Pakistan — and many other countries — even when vaccines eventually arrive.

Misinformation about Covid-19 is rife in Pakistan. Many people refuse to believe the virus even exists, and therefore they don’t plan to take a vaccine even if it is offered.

The National Library of Medicine in the US released a study in June 2020 warning that the threat of vaccine hesitancy in Pakistan would hamper the country’s Covid-19 efforts — and advised measures to counteract the “misleading narratives.” Pakistan is “quite vulnerable to such conspiracy narratives and has experienced failures of polio vaccination programs because of such claims,” the study said.
Pakistan’s failure to stop the spread of polio is due in part to a historical distrust of foreign healthcare providers, concerns that were inflamed after allegations surfaced that US intelligence officials had used a fake vaccination program in the city of Abbottabad as part of efforts to capture Osama bin Laden in 2011.

“My apprehension is the acceptability amongst the general population,” says Salahuddin, from Indus Hospital. “The average man on the street is not very impressed with the whole pandemic, they are in denial, and they may not even want to take the vaccine.”

In a bustling outdoor market in the capital Islamabad, motorbikes snake past the roadside vendors, and families mill around the stalls — shopping for mobile phones, fresh vegetables, or snacking on fresh bread and kebabs. Masks are on sale in one stall, but most people don’t wear them.

“In Pakistan, the first thing is that mostly people don’t believe that corona exists,” says customer Mohammad Armaghan, 21. “They just won’t get vaccinated.”

“There’s no need for a vaccine. This corona is nothing, we have faith in Allah, we don’t wear masks, we don’t need any protection,” says another customer, Ghulam Ali Chauhan.

Back at South City Hospital in Karachi, such misconceptions are what keeps Ahmad awake at night, worried that Pakistan could ultimately fail to emerge successfully from the coronavirus crisis.

“(The public) are in this impression that the disease does not exist,” she says. “That is a little bit scary, because then we don’t see the end to the peak, we don’t see the end to the disease. And with no vaccine in the near future, the peak could prolong for a very long time.”

Read original article here

Monoclonal antibodies benefit high-risk COVID-19 patients

CLOSE

The first COVID case in the U.S. was found in January, 2020. One year later, the numbers surrounding the pandemic are alarming.

USA TODAY

While vaccines may help slow the COVID-19 pandemic over the next months, drug company Eli Lilly announced Tuesday that its treatments can help save lives in the meantime. 

The company’s drug bamlanivimab was authorized by the U.S. Food and Drug Administration late last year and has been used by 125,000 high-risk patients nationwide based on early-stage data suggesting it could be effective.  

The drug is a monoclonal antibody, meaning it mimics one of the natural antibodies the immune system uses to fight off the virus.

Former President Donald Trump as well as former New Jersey Gov. Chris Christie and former New York City Mayor Rudy Giuliani all received monoclonal antibodies shortly after they were diagnosed with COVID-19.

In a large, late-stage study the company unveiled Tuesday, bamlanivimab combined with another monoclonal antibody, etesevimab, was found to be extremely effective in high-risk patients diagnosed with COVID-19.

Among patients who received a placebo, 10% of those at high risk ended up in the hospital, compared to just 2% of those who received the drug cocktail – a 70% drop. Patients were diagnosed an average of four days before treatment.

Trump touted monoclonal antibodies: Why aren’t more people getting them?

None of the 518 patients who got the cocktail died, compared to eight deaths among an equal-sized group of people with COVID-19 who received a placebo. 

The single drug and the cocktail performed equally well, said Lilly’s chief scientific officer Dr. Daniel Skovronsky, but the company is going to switch to making the combination once it receives FDA authorization.

The combination is more likely to remain effective, he said at an afternoon news conference, as the virus that causes COVID-19 evolves, leading to new variants.

“Bamlanivimab alone is predicted to be effective against more than 99% of all strains that we see in the United States today,” he said. “Bamlanivimab plus etesevimab should take care of the rest of them.”

The company may also add a third or fourth monoclonal as needed in the future to manage any variants that escape the current two-drug combination, he said.

An earlier Lilly study also showed that bamlanivimab can reduce serious disease among nursing home residents at high risk for COVID-19 and in the early days after infection.  

In future trials, Lilly will compare its proposed treatments against this combination, Skovronsky said, rather than against a placebo. Because the combination is so effective, it would be unethical to give high-risk patients a placebo, he said. 

There are 100,000 doses of bamlanivimab available today to patients around the world and another 250,000 will become available by the end of the quarter, Skovronsky said. 

Is it too little, too late? US officials urge Americans to ask their doctors about monoclonal antibodies for COVID

The U.S. government has bought hundreds of thousands of doses of Lilly’s and another combination antibody from Regeneron.

But many doses remain on shelves, unused, because of the difficulties of providing the drug to patients. 

To get a benefit, people have to receive the drug within the early stages of disease – once hospitalized with COVID-19, the drug does nothing to help, a Lilly study has shown.

Patients may not learn about the drugs until it’s too late, though.

At an early stage of the disease, people are particularly contagious, and hospitals, overrun with COVID-19 patients, have had a hard time making the time and space to deliver monoclonal antibodies. The drugs are delivered via infusion, like chemotherapy, rather than through a quick injection.

Skovronsky said Lilly is trying to speed up the time it takes to deliver the infusion and has gotten it down to under 20 minutes from an hour, which should make it easier to deliver. 

Finally, several physicians’ groups, including the Infectious Disease Society of America, have not recommended the drugs in their treatment guidelines, citing a lack of definitive evidence. Skovronsky said he hopes the new data will be enough to convince doctors to recommend monoclonal antibodies to their high-risk COVID-19 patients.

The company’s future studies will focus on testing whether smaller doses can help extend the predicted supply of the two monoclonal antibodies. It won’t be easy to produce more drug, said Lilly chairman and CEO David Ricks, but the drug that is made can be stretched further if lower doses can be used.

The recent studies tested 2,800 mg of each of the two monoclonals, and earlier studies had examined doses as high as 7,000 mg. But if only 700 mg can produce nearly as much benefit, the available supply will go much further, he said.

“A dose that could spread the available supply by a factor of two, three, or four to have the maximum human impact – that’s what we need to do now,” Ricks said. 

For more information about bamlanivimab in the U.S., Lilly has set up a 24-hour support line at 1-855-545-5921. Patients and physicians can also visit covid.infusioncenter.org or the HHS Therapeutic Distribution locator to find a potential treatment location.

Contact Karen Weintraub at kweintraub@usatoday.com.

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

Autoplay

Show Thumbnails

Show Captions

Last SlideNext Slide

Read or Share this story: https://www.usatoday.com/story/news/health/2021/01/26/eli-lilly-monoclonal-antibodies-high-risk-covid-19-patients-coronavirus/4263087001/

Read original article here

The Ultimate News Site